These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 19484470)

  • 21. [Phase II study of mitoxantrone].
    Tada A; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Adachi K; Nakada H; Okada Y
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1649-54. PubMed ID: 6476838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.
    Ahmann FR; Meyskens FL; Jones SE; Bukowski RM; Saiers JH; Ryan DH; Costanzi J; Vaughn CB; Coltman CA
    Cancer Treat Rep; 1983; 67(7-8):697-700. PubMed ID: 6688199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipophilic modification of salirasib modulates the antiproliferative and antimigratory activity.
    Ballari MS; O J Porta E; Zalazar EA; Etichetti CMB; Padrón JM; Girardini JE; Labadie GR
    Bioorg Med Chem; 2023 Sep; 92():117417. PubMed ID: 37531922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats.
    da Silva Morais A; Saliez A; Leclercq I; Horsmans Y; Stärkel P
    Clin Sci (Lond); 2008 Jan; 114(1):73-83. PubMed ID: 17678500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Farnesylthiosalicylic acid induces caspase activation and apoptosis in glioblastoma cells.
    Amos S; Redpath GT; Polar G; McPheson R; Schiff D; Hussaini IM
    Cell Death Differ; 2006 Apr; 13(4):642-51. PubMed ID: 16239932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
    Alberts DS; Mackel C; Pocelinko R; Salmon SE
    Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid.
    Reif S; Aeed H; Shilo Y; Reich R; Kloog Y; Kweon YO; Bruck R
    J Hepatol; 2004 Aug; 41(2):235-41. PubMed ID: 15288472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
    Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM
    Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
    Advani RH; Hurwitz HI; Gordon MS; Ebbinghaus SW; Mendelson DS; Wakelee HA; Hoch U; Silverman JA; Havrilla NA; Berman CJ; Fox JA; Allen RS; Adelman DC
    Clin Cancer Res; 2010 Apr; 16(7):2167-75. PubMed ID: 20233886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors.
    Silver BA; Barlock AL; Lippman ME; Anderson T; Fisher RI
    Cancer Treat Rep; 1982 May; 66(5):1229-30. PubMed ID: 6211231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preliminary results of a phase II trial on solid tumors of detorubicin, a new anthracyclin.
    Cancer Clin Trials; 1980; 3(2):115-20. PubMed ID: 7428135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel farnesylthiosalicylate (FTS)-eluting composite structures.
    Kraitzer A; Kloog Y; Zilberman M
    Eur J Pharm Sci; 2009 Jun; 37(3-4):351-62. PubMed ID: 19491026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I clinical and pharmacokinetic trial of hepsulfam.
    Ravdin PM; Havlin KA; Marshall MV; Brown TD; Koeller JM; Kuhn JG; Rodriguez G; Von Hoff DD
    Cancer Res; 1991 Dec; 51(23 Pt 1):6268-72. PubMed ID: 1933887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death.
    Blum R; Jacob-Hirsch J; Amariglio N; Rechavi G; Kloog Y
    Cancer Res; 2005 Feb; 65(3):999-1006. PubMed ID: 15705901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
    Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
    Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.
    Hamilton AL; Eder JP; Pavlick AC; Clark JW; Liebes L; Garcia-Carbonero R; Chachoua A; Ryan DP; Soma V; Farrell K; Kinchla N; Boyden J; Yee H; Zeleniuch-Jacquotte A; Wright J; Elliott P; Adams J; Muggia FM
    J Clin Oncol; 2005 Sep; 23(25):6107-16. PubMed ID: 16135477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A first-in-human study of conatumumab in adult patients with advanced solid tumors.
    Herbst RS; Kurzrock R; Hong DS; Valdivieso M; Hsu CP; Goyal L; Juan G; Hwang YC; Wong S; Hill JS; Friberg G; LoRusso PM
    Clin Cancer Res; 2010 Dec; 16(23):5883-91. PubMed ID: 20947515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
    Laheru D; Shah P; Rajeshkumar NV; McAllister F; Taylor G; Goldsweig H; Le DT; Donehower R; Jimeno A; Linden S; Zhao M; Song D; Rudek MA; Hidalgo M
    Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.